Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 70, Issue 2, Pages 213-220
Publisher
Springer Nature
Online
2012-06-08
DOI
10.1007/s00280-012-1899-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis
- (2011) Xiuli Liu et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Current Status of Developments and Applications of Micro-CT
- (2011) Erik L. Ritman Annual Review of Biomedical Engineering
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
- (2011) Peter D. Boasberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
- (2011) S. J. Shuttleworth et al. CURRENT MEDICINAL CHEMISTRY
- In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
- (2011) K. M. Kinross et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy
- (2011) F. Kullmann et al. ONCOLOGY
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo
- (2010) Y. C. Henderson et al. MOLECULAR CANCER THERAPEUTICS
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
- (2010) Hengmiao Cheng et al. MedChemComm
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More